全國服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：Cephalexin 15686-71-2Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.
產(chǎn)品型號：abs47027448廠商性質(zhì)：生產(chǎn)廠家更新時間：2025-12-12訪 問 量：751產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
| 品牌 | absin | CAS | 15686-71-2 |
|---|---|---|---|
| 分子式 | C16H17N3O4S | 純度 | ＞98% |
| 分子量 | 347.39 | 貨號 | abs47027448 |
| 規(guī)格 | 50mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a synthetic glucocorticoid | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Cephalexin 15686-71-2
| 產(chǎn)品描述 | |
| 描述 | Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. |
| 純度 | ＞98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | tou孢氨芐；Cefalexin；Cephacillin |
| 外觀 | 白色或微黃色結(jié)晶性粉末 |
| 可溶性/溶解性 | DMSO : 2 mg/mL (5.75 mM) Water ：10 mg/mL (28.78 mM) |
| 生物活性 | |
| In vitro(體外研究) | Cephalexin uptake by human MATE1-expressing human embryonic kidney 293 cells exhibits saturable kinetics with K(m) = 5.9 mM and a bell-shaped pH profile with a maximum at pH 7.0. Cephalexin results in overestimation of glucose concentration, but only in the samples that contain the highest antimicrobial concentration (2,400microg/mL) and only for the tablet. Cephalexin increases the activity of superficial mucous cells and orifice mucous cells of gastric glands, and inhibits the activity of cervix mucous cells. |
| In vivo(體內(nèi)研究) | Cephalexin causes a slight prolongation of 1-stage prothrombin time (PT) and activated partial thromboplastin time (PTT) and slight decrease in fibrinogen concentration in healthy dogs. Cephalexin causes a significant increase in 1-stage PT and activated PTT, amoxicillin causes a significant increase in activated PTT, and enrofloxacin causes a significant decrease in fibrinogen concentration. Cephalexin results in high numbers of E. coli producing plasmid-mediated CMY-2 β-lactamase at the end of the treatment period in dogs. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | MetabolismTypes of disease Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：